GYY 4137 morpholine salt
Cat. No. 3658
Chemical Name: P-(4-Methoxyphenyl)-P-4-morpholinyl
Biological ActivitySlow-releasing H2S donor. Exhibits vasodilator and antihypertensive activity. Activity causes slow dilation of blood vessels in vitro and in vivo; does not influence vascular smooth muscle cell viability in culture. Water-soluble.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Liu et al (2013) Hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E-/- mice. Br.J.Pharmacol. [Epub ahead of print]. PMID: 23713790.
Lee et al (2011) The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 6 e21077. PMID: 21701688.
Whiteman et al (2010) The effect of hydrogen sulfide donors on lipopolysaccaride-induced formation of inflammatory mediators in macrophages. Antioxid.Redox.Signal. 12 1147. PMID: 19769459.
Li et al (2008) Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137). Circulation 117 2351. PMID: 18443240.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GYY 4137 morpholine salt from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GYY 4137 morpholine salt, supplier, GYY4137, morpholine, h2s, hydrogen, sulfide, sulphide, donors, slow, releasing, release, vasodilator, antihypertensives, Tocris Bioscience, Miscellaneous Compound products
Find multiple products by catalog number
New Products in this Area
Antibiotic; selective apoptosis inducer of CLL cellsTrolox
Antioxidant vitamin E derivative
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.